ReviewPharmaceutics2021
An Update on Mesoporous Silica Nanoparticle Applications in Nanomedicine.
Review in Pharmaceutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed.
- Smart Surface-Engineered Mesoporous Silica Nanoparticles for Brain Tumor Therapy: Overcoming the Blood-Brain Barrier for Advanced Theranostics.AAPS PharmSciTech · 2026Review
- Functional polysaccharide-based bioactive delivery systems for urinary and reproductive system therapeutics.Drug delivery and translational research · 2026Review
- Silica based nanocarriers for combination immunotherapy targeting the tumor immune microenvironment.Drug delivery and translational research · 2026Review
- Aptamer-Functionalized Nanocarriers for Bone and Joint Diseases: Engineering Design Rules and Translational Roadmap.Small science · 2026Article
- Article
- Data-driven visualization of silica-based nanobiomaterial dynamics for tissue regeneration.Microsystems & nanoengineering · 2026Article
- Next-generation Mesoporous Silica Nanoparticles: Precision-engineered Platforms for Ovarian Cancer Therapy.Current drug research reviews · 2026Review
- Combating Gram-negative infections: The role of antimicrobial peptides and nanotechnology in overcoming antibiotic resistance.Materials today. Bio · 2025Review
- Alginate coated mesoporous silica nanoparticles as oral delivery carrier of curcumin and quercetin to colon cancer: preparation, optimization, characterization, and anticancer activity.Drug delivery and translational research · 2025Article
- Small Interfering RNA Carriers for Oncotherapy: A Preclinical Overview.Pharmaceutics · 2025Review
- Mesoporous silica nanoparticle-based nanomedicine: Preparation, functional modification, and theranostic applications.Materials today. Bio · 2025Article
- Nanomedicine for chronic pain management: From pathophysiology to engineered drug delivery systems.Materials today. Bio · 2025Review
- Electrochemical glycoproteins sensor for sensitive diagnosis of PD: Ag@MSNs-MPBA as a specific signal amplifier and reporter.Mikrochimica acta · 2025Article
- Harnessing Microalgae as Sustainable Cell Factories for Polyamine-Based Nanosilica for Biomedical Applications.Molecules (Basel, Switzerland) · 2025Review
- Synthesis and characterization of cadmium sulfide and titania photocatalysts supported on mesoporous silica for optimized dye degradation under visible light.Scientific reports · 2025Article
- Unwinding the Threads of Mesoporous Silica Nanoparticles as Cutting-edge for the Management of Inflammation: An Updated Review.Current pharmaceutical biotechnology · 2025Review
- Acoustic immune reprogramming: a novel paradigm for spatiotemporally controlled immune regulation using ultrasound-responsive nanoplatforms.Frontiers in immunology · 2025Review
- Innovative applications of silicon dioxide nanoparticles for targeted liver cancer treatment.Frontiers in bioengineering and biotechnology · 2025Review
- A Comprehensive Review: Mesoporous Silica Nanoparticles Greatly Improve Pharmacological Effectiveness of Phytoconstituent in Plant Extracts.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Enhancing docetaxel efficacy and reducing toxicity using biodegradable periodic mesoporous organosilica nanoparticles.Heliyon · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
The efficient and safe delivery of therapeutic drugs, proteins, and nucleic acids are essential for meaningful therapeutic benefits. The field of nanomedicine shows promising implications in the development of therapeutics by delivering diagnostic and therapeutic compounds. Nanomedicine development has led to significant advances in the design and engineering of nanocarrier systems with supra-molecular structures. Smart mesoporous silica nanoparticles (MSNs), with excellent biocompatibility, tunable physicochemical properties, and site-specific functionalization, offer efficient and high loading capacity as well as robust and targeted delivery of a variety of payloads in a controlled fashion. Such unique nanocarriers should have great potential for challenging biomedical applications, such as tissue engineering, bioimaging techniques, stem cell research, and cancer therapies. However, in vivo applications of these nanocarriers should be further validated before clinical translation. To this end, this review begins with a brief introduction of MSNs properties, targeted drug delivery, and controlled release with a particular emphasis on their most recent diagnostic and therapeutic applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.